The incidence and prevalence of XXXX , a nationwide study from 1955 through 2013.

@entity1 @entity101 @entity2012 @entity395 @entity4903
CONTEXT: @entity2012 is a @entity395 and increased mortality. The incidence and prevalence of @entity2012 worldwide is not well known. OBJECTIVE: To gather information on @entity1 diagnosed with acromegly in Iceland over 59  years. DESIGN: Information was retrospectively gathered about @entity1 diagnosed with @entity2012 from 1955 through 2013. Incidence was calculated from the total Icelandic population. SETTING/ @entity1 : Information was gathered from medical records at Landspitali National University Hospital, Iceland, housing the only endocrine department in the country, at the largest hospital outside of Reykjavik (Sj  krah  si      Akureyri, Akureyri Hospital) and the largest private outpatient clinic in Reykjavik, where some of the @entity1 received follow-up care. Further, information on @entity1 were sought from all endocrinologists treating adult @entity1 in Iceland. All @entity1 diagnosed with @entity2012 during the study period were included. RESULTS: Fifty-two @entity1 (32 @entity1 ) were diagnosed during the study period. The average age at diagnosis was 44.5  years. Nine @entity1 had died. Symptoms had been present for more than 3  years in most cases. Twenty-five @entity1 had @entity101 (48  %). Follow up information was available for 48 @entity1 , 63  % were considered cured after treatment. CONCLUSIONS: The incidence of @entity2012 in Iceland during the study period was much higher than earlier reports have indicated. During the last 9  years of the study 7.7 @entity1 were diagnosed per million per year. At diagnosis, 38  % had developed @entity101 and 10  % were diagnosed during follow up. This indicates the importance of @entity4903 in the aetiology of @entity101 .
